MARKETS
Blog

What Do General Partners Do? The Evidence-Based Breakdown

A
Auto Bot
Editorial Team
October 3, 2026 • 8 min read
What Do General Partners Do? The Evidence-Based Breakdown

What Do General Partners Actually Do? The Evidence-Based Breakdown

General partners just got hit with another carried-interest proposal. Profits taxed at capital-gains rates remain in the crosshairs. Again. That's another attempt, and it tells you everything about how exposed the GP role really is.

GPs are the ones who take the legal liability. Limited partners write the checks and stay shielded. GPs do everything else: source deals, run due diligence, decide exits. They collect management fees plus carried interest, but they also absorb the lawsuits, clawbacks, and reputational hits that LPs never see.

So what does that work actually look like?

---

The Legal Backbone: Why GPs Are on the Hook

In a limited partnership, the GP is personally and jointly liable for every obligation the fund incurs. Not theoretically. Contractually. Creditors can pursue the GP's balance sheet for fund obligations. The GP can be named in complaints related to portfolio companies. LPs risk only their committed capital; GPs risk everything else.

That liability shapes every decision. GPs can’t chase high-risk deals without downside protection. They structure investments with SPVs, escrows, and indemnification clauses. They owe fiduciary duties to LPs—meaning they can’t prioritize their own fees over the fund’s returns. Breach that duty, and they face lawsuits, regulatory penalties, or reputational damage that shuts down future fundraising.

Tax treatment adds another layer. Carried interest is taxed as long-term capital gains instead of ordinary income. Some call it a loophole for the wealthy; others say it aligns incentives with long-term performance. Either way, it’s a political lightning rod, and GPs keep lobbying to keep it.

---

Raising Capital: The Unseen Work Before the First Check

GPs don’t just manage money—they raise it first. The process involves negotiations with institutional LPs. These LPs commit capital but take a passive role. They don't source deals. That’s the GP’s job.

The limited partnership agreement (LPA) spells out the terms:

  • Management fees on committed capital, covering operating costs.
  • Carried interest on profits, after returning capital to LPs.
  • Hurdle rates before carry kicks in.
  • Clawback provisions: if early investments outperform but later ones fail, GPs may owe money back to LPs.

GPs often co-invest alongside LPs, putting their own capital at risk. That alignment matters—LPs trust GPs who have skin in the game. But co-investment means GPs share the downside without the liability shield LPs enjoy.

Capital raising isn’t just about securing commitments. It’s about setting expectations. LPs now demand transparency, ESG compliance, lower fees. They want real-time reporting, not quarterly updates. They're pushing back on carry, arguing it's too high in a low-return environment. GPs who ignore these demands lose LP support—and future fundraising becomes nearly impossible.

---

Deal Sourcing: The Hunt for Returns

GPs don’t wait for deals to come to them. They actively source them through networks, proprietary pipelines, industry relationships. In venture capital, that means various sourcing methods. In private equity, it's monitoring various opportunities.

Once a deal surfaces, due diligence begins. GPs assess:

  • Financials: revenue growth, margins, cash flow.
  • Market potential: size, competition, regulatory risks.
  • Competitive positioning: moats, differentiation, customer stickiness.
  • Management teams: track record, alignment, execution ability.

In VC, due diligence focuses on founder-market fit. Does the team have the grit and vision to scale? In PE, it’s operational efficiency. Can the GP cut costs, optimize supply chains, expand into new markets?

The GP’s role doesn’t end with the investment. It shifts to active management. In VC, that means supporting founders with recruiting, strategy, scaling. A GP might help a startup with various operational needs. In PE, it's restructuring companies.

Exit decisions are the GP’s call. They decide exit strategies. LPs approve major transactions, but the GP drives the strategy. A bad exit—selling too early, overpaying, missing a market window—can destroy a GP’s track record and make future fundraising nearly impossible.

---

Portfolio Management: The Hands-On Work

GPs don’t write checks and walk away. They actively manage portfolio companies: intervening when performance lags.

In VC, that might look like:

  • Intervening in management when needed.
  • Adjusting strategy when needed.
  • Helping with fundraising, introductions, crisis management.

In PE, it’s operational improvements:

  • Cutting costs.
  • Expanding into new markets.
  • Making acquisitions.

GPs monitor performance through various tools. If a portfolio company misses targets, the GP steps in.

The challenge? Managing a complex LP base. A single fund might have multiple LPs, each with different requirements. GPs must balance these demands while keeping the fund’s strategy on track. Ignore LP preferences, and they risk losing support, facing clawbacks, or struggling to raise the next fund.

---

Co-GP Structures: Sharing the Burden

Some funds now split the GP role between two firms. The firms share the general partner role. This reduces individual liability—if the fund gets sued, the risk is shared.

Co-GP models are common in large, complex deals where no single firm has all the expertise. Funds might partner with specialists. Funds might team up with operational firms.

But co-GP models introduce new challenges:

  • Coordination costs: more meetings, more alignment needed.
  • Decision-making conflicts: who has final say on exits?
  • Reputation risk: if one GP underperforms, the other gets dragged down.

The trend is still evolving, but it’s a sign of how the GP role is changing—from a single firm bearing all risk to a collaborative model with shared responsibilities.

---

Compensation: The 2-and-20 Model Under Fire

GPs typically earn:

  • Management fees on committed capital.
  • Carried interest on profits.

Management fees cover operating costs. Carried interest is where the controversy lies.

Why this percentage?

  • It aligns incentives—GPs only make money if LPs do.
  • It rewards long-term performance—GPs hold investments for extended periods.

Why is it controversial?

  • Tax treatment: carried interest is taxed as long-term capital gains instead of ordinary income.
  • Performance hurdles: some funds require minimum returns before carry kicks in, but others don’t—meaning GPs can profit even if LPs lose money.
  • Clawbacks: if early investments outperform but later ones fail, GPs may owe money back—but enforcement is rare.

The debate isn’t going away. Politicians keep proposing closing the carried-interest loophole. The industry keeps lobbying to maintain it. Pressure is growing, and GPs can’t assume the status quo will hold.

---

Hidden Challenges: Regulatory, Operational, Reputational Risks

Being a GP isn’t just about making money. It’s about managing risk—everywhere.

Regulatory scrutiny: GPs face various regulations and oversight. A single compliance failure can trigger fines, reputational damage, even criminal charges.

LP demands: institutional LPs now demand transparency, ESG compliance, lower fees. Ignore these trends, and GPs lose LP support—and future fundraising becomes nearly impossible.

Market cycles: GPs must navigate downturns, where portfolio companies struggle and exits dry up. Overleverage or misjudge macro trends, and years of returns can disappear.

Reputation risk: a single bad investment can destroy a GP’s track record. If a portfolio company collapses, LPs remember—and they walk.

The biggest risk? Misalignment with LPs. If a GP prioritizes short-term fees over long-term returns, LPs notice. If a GP ignores ESG mandates, LPs push back. Fail to deliver returns, and LPs take their money elsewhere.

---

The Future: AI, Automation, and Evolving Models

The GP role isn’t static. It’s evolving with technology, regulation, LP demands.

AI-driven deal sourcing: GPs use data analytics to identify opportunities. Various tools track founder movements, market trends, startup performance. AI automates due diligence, flagging red flags before humans review deals.

Automated platforms track performance in real time, reducing manual reporting. That frees GPs to focus on strategy instead of administrative work.

Hybrid GP-LP models: some LPs are taking more active roles, blurring the line between GP and LP. Some sovereign wealth funds co-invest alongside GPs, sometimes leading deals. This changes the dynamic—GPs no longer have a monopoly on deal flow, and LPs demand more influence over strategy.

Secondary markets: GPs sell stakes in funds to other investors, creating liquidity in an illiquid asset class. That lets GPs return capital early and raise new funds without waiting for exits. But it also introduces risks—if a GP sells a stake too cheaply, they undervalue their own carry.

---

Why the GP Role Is Still Irreplaceable—For Now

GPs are the operational, legal, and strategic engines of private capital. They raise money, deploy capital, manage risk, drive returns—all while bearing full liability. No algorithm, LP, or co-GP structure can fully replace what they do.

But the role is changing. AI automates deal sourcing. LPs demand more transparency. Co-GP models reduce individual liability. The traditional model—where a single firm controls everything—is evolving into something more collaborative, data-driven, LP-friendly.

The biggest question isn’t whether the GP role will survive. It’s how it will adapt. Will GPs become more like asset managers, relying on algorithms and outsourced operations? Or will they double down on human judgment, arguing no machine can replace their networks or crisis-management skills?

For now, the GP remains irreplaceable. But the tension between LPs and GPs—over fees, transparency, alignment—will shape the future of private capital. In a world where capital is abundant but trust is scarce, the GPs who deliver real value will thrive. The rest will struggle to raise their next fund.

Sources

Key Takeaways

  • The evolution of Blog continues to accelerate rapidly.
  • Experts like Auto Bot suggest staying informed on these specific developments.
  • Consider the broader implications for the tech industry moving forward.